2024-516899-15-00
Completed
Phase 1
A clinical study of MK-6916 in healthy people (MK-6916-002)
Merck Sharp & Dohme LLC1 site in 1 country40 target enrollmentStarted: December 6, 2024Last updated:
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 40
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Jonathan Kurz
Scientific
Merck Sharp & Dohme LLC
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
A clinical study of MK-5661 in healthy people (MK-5661-007)2024-520229-35-00Merck Sharp & Dohme LLC16
Completed
Phase 1
A Single-Ascending-Dose Study of MK6916 in Healthy Participants2024-510971-39-00Merck Sharp & Dohme LLC16
Active, not recruiting
Not Applicable
Single and Multiple Dose Study of MK-0616 in Healthy Japanese ParticipantsjRCT2031210233MSD K.K.48
Completed
Phase 2
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)Diabetic Neuropathy, PainfulNCT01564459Merck Sharp & Dohme LLC170
Completed
Not Applicable
Single Dose Study of MK-6194 in Healthy Japanese ParticipantsjRCT2051210183MSD K.K.48